Cancers, Vol. 13, Pages 5210: Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
Cancers, Vol. 13, Pages 5210: Novel Non-Immunologic Agents for Relapsed and Refractory Multiple Myeloma: A Review Article
Cancers doi: 10.3390/cancers13205210
Authors:
Arthur Bobin
Cécile Gruchet
Stéphanie Guidez
Hélène Gardeney
Laly Nsiala Makunza
Mathilde Vonfeld
Anthony Lévy
Laura Cailly
Florence Sabirou
Thomas Systchenko
Niels Moya
Xavier Leleu
Novel treatments are needed to address the lack of options for patients with relapsed or refractory multiple myeloma. Even though immunotherapy-based treatments have revolutionized the field in recent years, offering new opportunities for patients, there is still no curative therapy. Thus, non-immunologic agents, which have proven effective for decades, are still central to the treatment of multiple myeloma, especially for advanced disease. Building on their efficacy in myeloma, the development of proteasome inhibitors and immunomodulatory drugs has been pursued, and has led to the emergence of a novel generation of agents (e.g., carfilzomib, ixazomib, pomalidomide). The use of alkylating agents is decreasing in most treatment regimens, but melflufen, a peptide-conjugated alkylator with a completely new mechanism of action, offers interesting opportunities. Moreover, with the identification of novel targets, new drug classes have entered the myeloma armamentarium, such as XPO1 inhibitors (selinexor), HDAC inhibitors (panobinostat), and anti-BCL-2 agents (venetoclax). New pathways are still being e...
Source: Cancers - Category: Cancer & Oncology Authors: Arthur Bobin C écile Gruchet St éphanie Guidez H élène Gardeney Laly Nsiala Makunza Mathilde Vonfeld Anthony L évy Laura Cailly Florence Sabirou Thomas Systchenko Niels Moya Xavier Leleu Tags: Review Source Type: research